<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GUANFACINE HYDROCHLORIDE</span><br/>(gwahn'fa-seen)<br/><span class="topboxtradename">Tenex<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">central-acting antihypertensive</span><br/><b>Prototype: </b>Methyldopa<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg, 2 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Central-acting antihypertensive with alpha<sub>2</sub>-adrenergic agonist properties. In cerebral cortex, stimulation of alpha<sub>2</sub>-adrenoceptors triggers inhibitory neurons to reduce central sympathetic outflow (i.e., impulses from vasomotor center to
         heart and blood vessels).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Results in decreased peripheral vascular resistance and a slightly reduced (5 bpm) heart rate. Cardiac output is not altered
         by this agent.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of mild to moderate hypertension.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Adjunct in heroin withdrawal.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Treatment of acute hypertension associated with toxemia of pregnancy; pregnancy (category B); children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Severe coronary insufficiency, recent MI, cerebrovascular disease; chronic renal or hepatic failure; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 mg/d h.s., may be gradually increased to 3 mg/d if needed<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Take single dose at bedtime to reduce effect of somnolence.</li>
<li>Discontinue treatment gradually with planned tapering of schedule.</li>
<li>Store tablets at 15°30° C (59°86° F) in tightly closed container; protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Confusion, amnesia, mental depression, drowsiness, <span class="speceff-common">dizziness, sedation,</span> headache, asthenia, <span class="speceff-common">fatigue,</span> insomnia. <span class="typehead">CV:</span> Bradycardia, palpitation, substernal pain. <span class="typehead">Special Senses:</span> Rhinitis, tinnitus, taste change; vision disturbances, conjunctivitis, iritis. <span class="typehead">GI:</span> <span class="speceff-common">Dry mouth, constipation,</span> abdominal pain, diarrhea, dysphagia, nausea. <span class="typehead">Urogenital:</span> <span class="speceff-common">Impotence,</span> testicular disorder, urinary incontinence. <span class="typehead">Musculoskeletal:</span> Leg cramps, hypokinesia. <span class="typehead">Skin:</span> Dermatitis, pruritus, purpura, sweating. <span class="typehead">Other:</span> Dyspnea. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> and other <span class="classification">cns depressants</span> compound sedation and CNS depression. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 2 h. <span class="typehead">Peak:</span> 6 h. <span class="typehead">Duration:</span> Up to 24 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 80% excreted in the urine in 24 h. <span class="typehead">Half-Life:</span> 17 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Do not discontinue abruptly; may cause plasma and urinary catecholamine increases leading symptoms of tachycardia, insomnia,
            anxiety, nervousness. Rebound hypertension (i.e., increases in BP to levels significantly greater than those before therapy)
            may occur 27 d after abrupt drug withdrawal, but serious effects rarely develop.
         </li>
<li>Monitor BP until it is stabilized. Report a rise in pressure that occurs toward end of dose interval; a divided dose schedule
            may be ordered.
         </li>
<li>Assess mental status and alertness. Adverse effects tend to be dose-dependent, increasing significantly with doses above 3
            mg/d.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Continue drug even after you feel well. This is a maintenance dosage regimen (dose and dose intervals). If 2 or more doses
            are missed, consult physician about how to reestablish dosage regimen.
         </li>
<li>Employ measures to keep mouth moist; saliva substitutes (e.g., Moi-Stir, Xero-Lube) are available OTC. If dry mouth persists
            &gt;2 wk, patient should check with dentist.
         </li>
<li>Do not drive or engage in other potentially hazardous tasks requiring alertness until response to drug is known.</li>
<li>Avoid alcohol and do not self-medicate with OTC drugs such as sleeping medications, or cough medications without consulting
            physician.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>